Navigation Links
Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis

IRVINE, Calif.--(BUSINESS WIRE)--Jul 6, 2007 - Cobalis Corp. (OTCBB:CLSC), a pharmaceutical development company specializing in anti-allergy medications, today reported preliminary top-line results from two Phase III clinical trials for its drug PreHistin(TM) in patients with moderate to moderately severe seasonal allergic rhinitis, commonly known as hay fever. The trials showed very low symptom levels in both placebo and PreHistin-treated patient groups, thereby leaving no room to demonstrate a meaningful drug effect.

In the randomized, six week, placebo-controlled trials involving a total of 1,551 subjects, PreHistin did not achieve statistically significant differences from placebo in the primary measure of efficacy, the reduction in total nasal symptom score (TNSS). However, the TNSS data for placebo-treated patients was far lower than would be expected for the moderate to moderately severe patient population called for in the protocol. Low pollen counts in many of the regions during the time PreHistin was being tested may have resulted in low mean placebo symptom scores for the overall study population.

The trials showed that PreHistin was well tolerated and thus contributed positively to the safety record of PreHistin's active ingredient, cyanocobalamin.

A comparison of pre- and post-treatment blood levels of cobalamin demonstrated for the first time in a large study population that delivery of cyanocobalamin via sublingual lozenges resulted in significant increases in cobalamin blood levels.

Cobalis' Chief Scientific Officer Ernest Armstrong commented: "Showing a meaningful reduction in allergy symptoms when the symptoms never increased throughout the pollen season to the desired moderate to moderately severe level is next to impossible. It's like trying to prove that a pump can pump water out of a swimming pool when there is almost no water in the pool to begin with. Other pharmaceu
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cobalis Expects to Report Phase III Top-Line Results in May
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:8/26/2014)... , Aug. 27, 2014 Higher ... insurance are fuelling the demand for medical devices ... rise of medical tourism, the inflow of patients ... The market will continue its steady ascent as ... age-related and non-communicable diseases, compelling significant investments in ...
(Date:8/26/2014)... plc (NYSE: ACT ), a leading global specialty ... and President of Actavis, will provide an overview and update ... Conference 2014 in New York, NY . ... presentation will take place on Tuesday, September 9, 2014 at ... 109 East 42 nd Street, New York, ...
(Date:8/26/2014)... -- Research and Markets  has announced the addition ... report to their offering. Intranasal drug ... administration of drugs for the treatment of local diseases ... and non-allergic rhinitis and sinusitis. The nose is considered ... and systematic drug delivery. Continuous technological ...
Breaking Medicine Technology:Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 2Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 3Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 4Actavis to Present at Morgan Stanley Global Healthcare Conference 2014 2Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 2Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 3
... Inc. (Nasdaq: BNVI ) announced today the publication ... of tamoxifen on estrogen receptor beta (ERb) gene regulation. ... in Molecular and Cellular Endocrinology, demonstrate that tamoxifen inhibits ... breast cancer cell proliferation. , "Tamoxifen has been ...
... , BEIJING, Oct. 20 /PRNewswire-Asia-FirstCall/ ... "the Company") a leading manufacturer, developer,and distributor of Shengmingsu ... of China (PRC), today announced that the Company consummated,the ... of October,16, 2009. , Yongye ...
Cached Medicine Technology:Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta 2Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta 3Yongye International Announces Completion of Restructuring 2Yongye International Announces Completion of Restructuring 3
(Date:8/27/2014)... August 27, 2014 The Global and ... study on the current state of the Maleic Anhydride ... a basic overview of the industry, including definitions, applications ... domestic market analysis are provided with a focus on ... A comparison between the international and Chinese situation is ...
(Date:8/27/2014)... Australia (PRWEB) August 27, 2014 ... erratic climatic conditions and fluctuations in global supply and ... the past five years. The industry derives a large ... are subject to global market dynamics, with supply and ... Brazil and India. A strong Australian dollar for the ...
(Date:8/27/2014)... August 27, 2014 UNIWIGS, one of the leading ... pieces, offers big deals and sales on all its products, for ... products can save much on UniWigs hair products in ... they can save $10 with a coupon code LABOR10; while when ... coupon code LABOR50. Besides this deal which coupon code is needed ...
(Date:8/27/2014)... Co-operative Research Centre into Microtechnologies, is coordinating ... innovative solutions based on microtechnologies to tackle ... life sciences, among others. IK4-Ikerlan, Ceit-IK4, IK4-Tekniker, ... with CIC microGUNE on this project, which ... Etortek 2013-2014 programme of the Government of ...
(Date:8/27/2014)... 27, 2014 Catalent, the leading ... solutions for drugs, biologics and consumer health products, ... held Australian biomarker research company, Minomic International Limited, ... for prostate cancer therapy. Under the agreement, Catalent ... study with a view to larger scale production ...
Breaking Medicine News(10 mins):Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 2Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 3Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 4Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 5Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:UniWigs Is Offering A Big Sale for Labor Day on All Its Products 2Health News:Microtechnologies for driving forward mobility and human health 2Health News:Catalent and Minomic Collaborate to Bring New Prostate Cancer Treatment to Market 2Health News:Catalent and Minomic Collaborate to Bring New Prostate Cancer Treatment to Market 3
... colleagues from the Institute of Child Health will be studying ... The study will focus on the changes in their brain ... identify and understand the problems in their brain which could ... study is being funded by the Action Medical Research, UK. ...
... grow and currently affects more that 18 million ... need for alternative diabetes therapies with earlier more ... of insulin by the lung may provide an ... alternative insulin delivery systems must meet certain pharmacokinetic ...
... as the Breast Cancer Awareness Month. It is a sad ... and mortality associated with breast cancer//, very few men and ... risk factors and what is to be done in case ... Lauder, founder and president of the Breast Cancer Research Foundation, ...
... Los Angles have taken a major step forward in the ... the development of prostate cancer in animals//. ,The antibody ... and according to Dr. Robert E. Reiter, a professor of ... study's senior author it tells the cancer that it is ...
... known to express endogenous peptide antibiotics called defensins, ... active against bacteria, fungi and viruses//. ... of Nature, describes plectasin-the first defensin to be ... nigrella. Plectasin has primary, secondary and tertiary structures ...
... the deadly HIV/AIDS is accelerating in China with 126,808 ... patients, according to latest health reports//. Experts estimate that ... 80,000 AIDS patients. ,This is considerably higher than the ... over a margin of 19,818. In addition, the patients ...
Cached Medicine News:Health News:New Research To Study Brain Changes In Premature Births 2Health News:HIIP- A Novel Inhaled Insulin Delivery System As An Alternative To Injectable Insulin Therapy 2Health News:Mushroom found to be a source of a new antibiotic: Plectasin 2
... with ease of use make the OM-5 ... Ideal for office or hospital-based urodynamics, the ... cystometry, leak point pressure, or urethral pressure ... make the OM-5 flexible enough to meet ...
Windows-Based Urodynamics for Fast and Straightforward. Testing For Clinics Where Logic and Efficiency are at a Premium...
... The Corkscrew FT II (fully threaded) ... anchor designed to be inserted flush with ... strength and anchor stability. The full thread ... suture anchors with protruding eyelets. Especially advantageous ...
... (fully threaded) is a 5.5 mm diameter ... flush with the cortical bone surface to ... fully threaded design substantially improves pull-out strength ... The fully threaded design prevents anchor pull-back ...
Medicine Products: